Wednesday, September 2, 2009

Have no fear ST-246 is here.....

SIGA Technologies has received a $3 Million Phase II Research Grant from the NIG to aid in the research and development of ST-246, a pharmaceutical agent that can treat the adverse reactions to the Smallpox Vaccine. This could be used as an adjunct to the current smallpox vaccine.

SIGA will use the grant to evaluate the efficacy of ST-246 in preventing smallpox vaccine-related adverse events in primate models of immunodeficiency and will then evaluate the impact of the concurrent ST-246 administration on the Vaccinia (ACAM2000) vaccination efficacy in a monkeypox challenge in non-human primate models of immunodeficiency.

There is hope for those who are immunodeficient!

No comments:

Post a Comment